Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Multiple Myeloma Drugs Market From 2025 to 2029?

The market for multiple myeloma drugs has seen robust expansion in the past few years. Projected to increase from $21.84 billion in 2024 to $23.03 billion in 2025, it anticipates a compound annual growth rate (CAGR) of 5.4%. Factors influencing growth during the historical duration include enhanced diagnostic methods, victorious clinical trials, better comprehension of the disease pathology, advancements in healthcare infrastructure, active patient representation, and heightened awareness.

The market size for multiple myeloma drugs is projected to experience robust expansion in the forthcoming years, with an estimation to reach $29.44 billion by 2029 at a compound annual growth rate (CAGR) of 6.3%. This anticipated growth in the prediction period can be credited to advancements in immunotherapy, broadening of targeted therapies, the application of liquid biopsies, the rise of car-t cell therapy, and the discovery of biomarkers. Noteworthy trends during the forecast period encompass an increased emphasis on long-term survivorship, the investigation of epigenetic therapies, the extended role of telemedicine, widened access to innovative therapies, and sustainability in myeloma treatment.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

What Elements Are Contributing To Growth In The Multiple Myeloma Drugs Market?

The multiple myeloma drugs market is predicted to grow due to the increasing incidence of hematological cancer. Such cancers have their origin in the blood-forming tissues like bone marrow or immune system cells, covering diseases like leukemia, lymphoma, multiple myeloma, and more. Medications targeted towards multiple myeloma often aid in treating various myelomas by destroying the cancer cells and restricting their proliferation. These drugs diminish the cell division process, stimulate multiple enzymatic activities, and help in maintaining bone strength while reducing pain from deteriorating bones. For instance, data from the American Cancer Society (ACS), a US-based organization committed to eradicating cancer, revealed that in January 2023, around 59,610 new leukemia cases and roughly 20,380 cases of acute myeloid leukemia (AML) were diagnosed. Furthermore, leukemia was responsible for 23,710 deaths. Consequently, the rising incidence of hematological cancer is propelling the growth of the multiple myeloma drugs market.

Which Segments Are Detailed In The Global Multiple Myeloma Drugs Market Report?

The multiple myeloma drugs market covered in this report is segmented –

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

Which Emerging Trends And Strategic Shifts Are Shaping The Multiple Myeloma Drugs Market?

In the multiple myeloma drugs market, product innovation is becoming a significant trend. Key players in the market are concentrating on the development of new and innovative products to consolidate their market standing and attain a competitive edge. For example, in March 2022, Janssen Biotech Inc., a Japanese biotech firm, secured the approval of the US Food and Drug Administration for Carvykti, a CAR T-Cell therapy (also known as personalized immunotherapy) for multiple myeloma. CARVYKTI (ciltacabtagene autoleucel) is an engineered cell-based remedy involving T cells externally altered with a non-replicative lentiviral vector that carries an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR). This receptor consists of two single-domain antibodies paired to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Patients who have undergone a minimum of four therapy lines, including specific types of multiple myeloma medicines (an immunomodulator, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), can utilize this treatment for relapsed conditions.

Who Are The Key Contributors To Growth In The Multiple Myeloma Drugs Market?

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Which Region Is Projected To Lead The Multiple Myeloma Drugs Market By 2025?

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model